Find, compare & contact
Radalbuvir
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Radalbuvir API 1314795-11-3?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Radalbuvir. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Radalbuvir
- Synonyms:
- Cas Number:
- 1314795-11-3
- DrugBank number:
- DB12065
- Unique Ingredient Identifier:
- 273K4V0SPC
General Description:
Radalbuvir, identified by CAS number 1314795-11-3, is a notable compound with significant therapeutic applications. Radalbuvir has been used in trials studying the treatment of Chronic Hepatitis C, Chronic HCV Infection, and Chronic Hepatitis C Infection.
Classification:
Radalbuvir belongs to the class of organic compounds known as thiophene carboxylic acids. These are compounds containing a thiophene ring which bears a carboxylic acid group, classified under the direct parent group Thiophene carboxylic acids. This compound is a part of the Organic compounds, falling under the Organoheterocyclic compounds superclass, and categorized within the Thiophenes class, specifically within the Thiophene carboxylic acids and derivatives subclass.
Categories:
Radalbuvir is categorized under the following therapeutic classes: Sulfur Compounds. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Radalbuvir is a type of Anti-HCV agents
Anti-HCV agents, belonging to the pharmaceutical API category, are potent medications used in the treatment of Hepatitis C Virus (HCV) infection. Hepatitis C is a viral disease that affects the liver and can lead to severe health complications if left untreated. Anti-HCV agents work by targeting specific mechanisms involved in the replication and spread of the HCV virus within the body.
These pharmaceutical APIs are designed to inhibit various steps of the viral lifecycle, including viral entry into liver cells, viral RNA replication, and assembly of new viral particles. By disrupting these critical processes, anti-HCV agents effectively reduce the viral load in the body, slow down disease progression, and ultimately improve patient outcomes.
The development of anti-HCV agents has revolutionized the management of HCV infection, offering new hope for patients. These APIs are often used in combination with other antiviral drugs to form highly effective treatment regimens known as direct-acting antiviral (DAA) therapies. DAAs have significantly higher cure rates compared to older treatment options, such as interferon-based therapies, and are associated with fewer side effects.
The pharmaceutical industry has made significant advancements in the development of anti-HCV agents, resulting in a diverse range of APIs with varying mechanisms of action. This diversity allows healthcare professionals to tailor treatment plans based on the specific characteristics of each patient's HCV infection, maximizing the chances of successful viral eradication.
In summary, anti-HCV agents are a crucial category of pharmaceutical APIs used in the treatment of Hepatitis C. Their targeted action against the HCV virus has revolutionized the management of this chronic infection, providing more effective and better-tolerated treatment options for patients.
